Predictive Oncology Inc. (NasdaqCM: POAI) Loss Submission Form

Kuznicki Law is investigating the proposed sale of Predictive Oncology Inc. (NasdaqCM: POAI) to Renovaro Inc. (NasdaqCM: RENB). Under the terms of the binding letter of intent, Predictive Oncology will be merged into Renovaro in exchange for a newly created series of preferred stock of Renovaro. The preferred stock will be issued to shareholders of Predictive Oncology in a 1:1 exchange for their existing Predictive Oncology common stock. Kuznicki Law is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.